日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers

Nanrilkefusp alfa (SOT101) 是一种 IL-15 受体 βγ 超激动剂,可作为单药或与抗 PD-1 药物联合用于治疗晚期癌症患者。

Stephane Champiat ,Elena Garralda ,Vladimir Galvao ,Philippe A Cassier ,Carlos Gomez-Roca ,Iphigenie Korakis ,Peter Grell ,Aung Naing ,Patricia LoRusso ,Romana Mikyskova ,Nada Podzimkova ,Milan Reinis ,Kaissa Ouali ,Andreu Schoenenberger ,Joachim Kiemle-Kallee ,Sascha Tillmanns ,Richard Sachse ,Ulrich Moebius ,Radek Spisek ,David Bechard ,Lenka Palova Jelinkova ,Irena Adkins ,Aurelien Marabelle

Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v.

新型 PD-1 靶向、活性优化的 IL-15 突变体 SOT201 以顺式作用提供优于 PD1-IL2v 的抗肿瘤活性

Matuskova Hana, Marasek Pavel, Mazhara Vladyslav, Simonova Ekaterina, Kosinova Lucie, Danek Petr, Danova Klara, Sajnerova Katerina, Malatova Iva, Hrabankova Klara, Greco Denise, Martinec Ondrej, Fabisik Matej, Podzimkova Nada, Hladikova Kamila, Behalova Katerina, Antosova Zuzana, Sirova Milada, Mikyskova Romana, Reinis Milan, Kovar Marek, Béchard David, Moebius Ulrich, Palova Jelinkova Lenka, Spisek Radek, Steegmaier Martin, Adkins Irena

Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1+CD8+ T Cells in Metastatic Ovarian Cancer

化疗驱动转移性卵巢癌中与免疫检查点抑制剂(ICI)反应性TCF1+CD8+ T细胞相关的三级淋巴结构

Lanickova, Tereza; Hensler, Michal; Kasikova, Lenka; Vosahlikova, Sarka; Angelidou, Artemis; Pasulka, Josef; Griebler, Hannah; Drozenova, Jana; Mojzisova, Katerina; Vankerckhoven, Ann; Laco, Jan; Ryska, Ales; Dundr, Pavel; Kocian, Roman; Cibula, David; Brtnicky, Tomas; Skapa, Petr; Jacob, Francis; Kovar, Marek; Praznovec, Ivan; McNeish, Iain A; Halaska, Michal J; Rob, Lukas; Coosemans, An; Orsulic, Sandra; Galluzzi, Lorenzo; Spisek, Radek; Fucikova, Jitka

Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer

三级淋巴结构和B细胞决定卵巢癌中具有临床意义的T细胞表型

Kasikova, Lenka; Rakova, Jana; Hensler, Michal; Lanickova, Tereza; Tomankova, Jana; Pasulka, Josef; Drozenova, Jana; Mojzisova, Katerina; Fialova, Anna; Vosahlikova, Sarka; Laco, Jan; Ryska, Ales; Dundr, Pavel; Kocian, Roman; Brtnicky, Tomas; Skapa, Petr; Capkova, Linda; Kovar, Marek; Prochazka, Jan; Praznovec, Ivan; Koblizek, Vladimir; Taskova, Alice; Tanaka, Hisashi; Lischke, Robert; Mendez, Fernando Casas; Vachtenheim, Jiri Jr; Heinzelmann-Schwarz, Viola; Jacob, Francis; McNeish, Iain A; Halaska, Michal J; Rob, Lukas; Cibula, David; Orsulic, Sandra; Galluzzi, Lorenzo; Spisek, Radek; Fucikova, Jitka

Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma

靶向肿瘤相关巨噬细胞以成功治疗卵巢癌

Truxova, Iva; Cibula, David; Spisek, Radek; Fucikova, Jitka

Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients

恶性原始细胞中的 I 型干扰素信号有助于 AML 患者的治疗效果

Peter Holicek, Iva Truxova, Jana Rakova, Cyril Salek, Michal Hensler, Marek Kovar, Milan Reinis, Romana Mikyskova, Josef Pasulka, Sarka Vosahlikova, Hana Remesova, Iva Valentova, Daniel Lysak, Monika Holubova, Petr Kaspar, Jan Prochazka, Lenka Kasikova, Radek Spisek, Lorenzo Galluzzi, Jitka Fucikova

Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial

自体树突状细胞免疫疗法、多西他赛和泼尼松与安慰剂治疗转移性去势抵抗性前列腺癌患者的疗效和安全性:VIABLE III期随机临床试验

Vogelzang, Nicholas J; Beer, Tomasz M; Gerritsen, Winald; Oudard, Stéphane; Wiechno, Pawel; Kukielka-Budny, Bozena; Samal, Vladimir; Hajek, Jaroslav; Feyerabend, Susan; Khoo, Vincent; Stenzl, Arnulf; Csöszi, Tibor; Filipovic, Zoran; Goncalves, Frederico; Prokhorov, Alexander; Cheung, Eric; Hussain, Arif; Sousa, Nuno; Bahl, Amit; Hussain, Syed; Fricke, Harald; Kadlecova, Pavla; Scheiner, Tomas; Korolkiewicz, Roman P; Bartunkova, Jirina; Spisek, Radek

Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial

树突状细胞免疫疗法 DCVAC/OvCa 联合一线化疗(卡铂联合紫杉醇)治疗上皮性卵巢癌的安全性和有效性:一项 II 期、开放标签、多中心、随机试验

Rob, Lukas; Cibula, David; Knapp, Pawel; Mallmann, Peter; Klat, Jaroslav; Minar, Lubos; Bartos, Pavel; Chovanec, Josef; Valha, Petr; Pluta, Marek; Novotny, Zdenek; Spacek, Jiri; Melichar, Bohuslav; Kieszko, Dariusz; Fucikova, Jitka; Hrnciarova, Tereza; Korolkiewicz, Roman Pawel; Hraska, Marek; Bartunkova, Jirina; Spisek, Radek

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

临床试验观察:基于树突状细胞(DC)的癌症免疫疗法

Laureano, Raquel S; Sprooten, Jenny; Vanmeerbeerk, Isaure; Borras, Daniel M; Govaerts, Jannes; Naulaerts, Stefan; Berneman, Zwi N; Beuselinck, Benoit; Bol, Kalijn F; Borst, Jannie; Coosemans, An; Datsi, Angeliki; Fučíková, Jitka; Kinget, Lisa; Neyns, Bart; Schreibelt, Gerty; Smits, Evelien; Sorg, Rüdiger V; Spisek, Radek; Thielemans, Kris; Tuyaerts, Sandra; De Vleeschouwer, Steven; de Vries, I Jolanda M; Xiao, Yanling; Garg, Abhishek D

SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity

SOT101 诱导 NK 细胞毒性并增强抗体依赖性细胞毒性和抗肿瘤活性

Zuzana Antosova, Nada Podzimkova, Jakub Tomala, Katerina Augustynkova, Katerina Sajnerova, Eva Nedvedova, Milada Sirova, Guy de Martynoff, David Bechard, Ulrich Moebius, Marek Kovar, Radek Spisek, Irena Adkins